Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.30 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7031752 | 0.81 | LMNA (0.34) | CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2 | |
| SCHEMBL13640136 | 0.80 | SMN1; SMN2 (0.36) | SMN1; SMN2ALDH1A1ITGB1ITGA4 | |
| SCHEMBL17268636 | 0.80 | CYP1A2 (0.33) | CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2 | |
| SCHEMBL7024731 | 0.79 | LMNA (0.33) | CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2 | |
| SCHEMBL15726059 | 0.78 | METAP2 (0.38) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL7030186 | 0.77 | CA1 (0.42) | CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2 | |
| SCHEMBL7034586 | 0.75 | SMN1; SMN2 (0.33) | CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2 | |
| SCHEMBL14353167 | 0.74 | LMNA (0.45) | LMNAALDH1A1TSHRHPGD | |
| SCHEMBL7460510 | 0.74 | LMNA (0.36) | CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2 | |
| SCHEMBL11885262 | 0.73 | GAA (0.38) | CYP2C9CYP2C19HTTSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180125986-A1 | Nitric Oxide Releasing Produgs of Therapeutic Agents | SATYAM APPARAO (IN) | 2018-05-10 | — | — | US | disclosed |
| US-9844599-B2 | Nitric oxide releasing produgs of therapeutic agents | SATYAM APPARAO (IN) | 2017-12-19 | — | — | US | disclosed |
| US-20150328323-A1 | Nitric Oxide Releasing Produgs of Therapeutic Agents | SATYAM APPARAO (IN) | 2015-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180125986-A1 | Nitric Oxide Releasing Produgs of Therapeutic Agents | NOS2, NOS1, NOS3 | CYP1A2 138/4885CYP2C9 230/4885CYP2C19 78/4885 |
| US-20150328323-A1 | Nitric Oxide Releasing Produgs of Therapeutic Agents | NOS2, NOS1, PTGIS | CYP1A2 164/4885CYP2C9 294/4885CYP2C19 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.